Pieris Pharmaceuticals, Inc. (PIRS) Company Sales Revenue

Corporate emblem and logo of Pieris Pharmaceuticals, Inc. (PIRS)

Pieris Pharmaceuticals (PIRS) is developing the Anticalin platform for the treatment of cancer and respiratory pathologies, leveraging clinical trial data and cost optimization. This chart illustrates the company's sales figures as reported by the GURU.Markets system, where 0.00 represents the latest metric reading. External contractors support development efficiency to maintain expenditure flexibility. Capitalization is based on royalties and upfront payments from global pharma behemoths for innovative protein-based drugs.

PIRS (Pieris Pharmaceuticals) Revenue and Sales Volume history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Pieris Pharmaceuticals

- market price and analyst price targets:
- market capitalization details:
Summary company analysis:Pieris Pharmaceuticals
Original product of Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals (PIRS) gross sales volume reflects the monetization efficiency of the Anticalin platform through licensing fees and royalties, determining the inertial value of the assets. This indicator measures total incoming cash flow, excluding reporting time lags, allowing investors to assess the business's fundamental ability to generate revenue and balance potential returns against the risks of a market drawdown.

Analysis of competing companies

HLN: Company Sales Revenue|Company Revenue Kenvue (KVUE)|VRNA (Verona Pharma Corp) - Company Sales Revenue|Company Revenue Jyong Biotech MENS|Ligand Pharma - Company Revenue|AMRX - Company Revenue|Company Total Revenue perrigo.com|ALVO (Alvotech SA) - Company Sales|Company Total Sales Volume Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Revenue and Sales Volume|ANIP: Company Sales Revenue|Company Revenue Afrezza (MNKD)|Revenue and Sales Volume amphastar.com (AMPH)|Revenue and Sales Volume PCRX (pacira.com)|Company Sales Revenue SPRY|Theravance Biopharma Inc - Revenue and Sales Volume|Company Gross Revenue Aquestive Therapeutics AQST|SCPH: Revenue and Sales Volume|Company Sales Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Revenue and Sales Volume|SXTC (China SXT Pharmaceuticals, Inc.) - Company Total Sales|Company Revenue eupraxiapharma.com (EPRX)|Company Total Sales BHST|Company Revenue eXoZymes EXOZ|Company Sales Revenue ORMP|ENTX - Company Revenue|HYFT: Company Revenue|ABVC BioPharma, Inc (ABVC) - Company Revenue|Cumberland Pharma - Company Sales Revenue|QNTM (Quantum BioPharma Corp) - Revenue and Sales Volume|FibroGen, Inc. - Company Annual Revenue|Revenue and Sales Volume TELO|Company Gross Revenue Rani Therapeutics Holdings, Inc.|Company Revenue Synergy CHC Corp. SNYR|Revenue and Sales Volume rallybio.com RLYB|Lexaria Bioscience Corp. - Revenue and Sales Volume|PULM: Company Revenue|PTHL (ftzy.com.cn) - Company Sales|APM: Company Total Sales|LYRA (Lyra Therapeutics Inc) - Revenue and Sales Volume|Company Sales Volume IBO (Impact BioMedical)|Company Sales TNFA (TNF Pharmaceuticals)|Revenue and Sales Volume cbdMD Corp (YCBD)|Revenue and Sales Volume PRFX (PainReform)|Company Gross Revenue Auris Medical (CYTO)|LIPO - Company Revenue|Optinose (OPTN) - Company Sales|Procaps Group SA (PROC) - Company Revenue|Company Annual Revenue PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding) - Revenue and Sales Volume|SLRN: Company Sales Revenue|Revenue and Sales Volume TFFP